Resource Summary Report

Generated by RRID on Sep 9, 2026

MOC1

RRID:CVCL_ZD32
Type: Cell Line

Proper Citation

RRID:CVCL_ZD32

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_ZD32

Proper Citation: RRID:CVCL_ZD32

Description: Cell line MOC1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Squamous cell carcinoma of the mouse oral cavity

Defining Citation: PMID:22086849, PMID:22434099, PMID:24668645, PMID:25729643

Comments: Characteristics: Indolent growth phenotype.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MOC1

Synonyms: Mouse Oral Cancer 1

Cross References: GEO:GSM1213076, GEO:GSM1213077, GEO:GSM1213078, GEO:GSM1213079, Kerafast:EWL001-FP, Millipore:SCC469, Wikidata:Q98127270

ID: CVCL_ZD32

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260905T181202+0000

Ratings and Alerts

No rating or validation information has been found for MOC1.

No alerts have been found for MOC1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

McIlvried LA, et al. (2026) CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma. Cell reports, 45(2), 116994.

Chen F, et al. (2026) CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(11), 2166.

Tsai TY, et al. (2026) The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. Translational oncology, 70, 102839.

Wang Q, et al. (2026) Androgen Receptor Signaling Induces CD8+ T-cell Dysfunction That Is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma. Cancer research, 86(9), 2286.

Zhang J, et al. (2026) RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity. Molecular cell.

Xu W, et al. (2026) PARD6G mediates resistance to PD-1 immune checkpoint blockade in head and neck squamous cell carcinoma. International immunopharmacology, 184, 116949.

Zhang Y, et al. (2025) CDK4/6 Inhibitor Priming Enhances PD-1 Blockade via Sellhi Neutrophil-Induced Stat5a+ Progenitor Exhausted CD8+ T Cell. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e10501.

Zhong W, et al. (2025) Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. Nature cancer, 6(7), 1157.

Grandis JR, et al. (2025) Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer. Cancer cell.

Li Y, et al. (2025) Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. Journal of translational medicine, 23(1), 403.

Tao ZY, et al. (2024) Lingual Denervation Improves the Efficacy of Anti-PD-1 Immunotherapy in Oral Squamous Cell Carcinomas by Downregulating TGF? Signaling. Cancer research communications, 4(2), 418.

Feng YY, et al. (2024) Synthetic lethal CRISPR screen identifies a cancer cell-intrinsic role of PD-L1 in regulation of vulnerability to ferroptosis. Cell reports, 43(7), 114477.

Tsai DE, et al. (2024) Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models. iScience, 27(9), 110854.

Gao J, et al. (2024) CCR7/DUSP1 signaling Axis mediates iCAF to regulates head and neck squamous cell carcinoma growth. Cellular signalling, 122, 111305.

Fay M, et al. (2024) TGF-? neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice. iScience, 27(8), 110520.

Saito S, et al. (2024) Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(9), 1934.

Li Y, et al. (2022) Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Molecular cell, 82(20), 3901.